Nothing Special   »   [go: up one dir, main page]

DE69432223D1 - Onkoprotein protein kinase - Google Patents

Onkoprotein protein kinase

Info

Publication number
DE69432223D1
DE69432223D1 DE69432223T DE69432223T DE69432223D1 DE 69432223 D1 DE69432223 D1 DE 69432223D1 DE 69432223 T DE69432223 T DE 69432223T DE 69432223 T DE69432223 T DE 69432223T DE 69432223 D1 DE69432223 D1 DE 69432223D1
Authority
DE
Germany
Prior art keywords
jnk
protein kinase
jun
activation domain
terminal activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69432223T
Other languages
English (en)
Other versions
DE69432223T2 (de
Inventor
Michael Karin
Masahiko Hibi
Anning Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26788998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69432223(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/094,533 external-priority patent/US5534426A/en
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of DE69432223D1 publication Critical patent/DE69432223D1/de
Application granted granted Critical
Publication of DE69432223T2 publication Critical patent/DE69432223T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
DE69432223T 1993-07-19 1994-07-18 Onkoprotein protein kinase Revoked DE69432223T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/094,533 US5534426A (en) 1993-07-19 1993-07-19 Oncoprotein protein kinase
US08/220,602 US6514745B1 (en) 1993-07-19 1994-03-25 Oncoprotein protein kinase
PCT/US1994/008120 WO1995003324A1 (en) 1993-07-19 1994-07-18 Oncoprotein protein kinase

Publications (2)

Publication Number Publication Date
DE69432223D1 true DE69432223D1 (de) 2003-04-10
DE69432223T2 DE69432223T2 (de) 2003-08-21

Family

ID=26788998

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432223T Revoked DE69432223T2 (de) 1993-07-19 1994-07-18 Onkoprotein protein kinase

Country Status (11)

Country Link
US (7) US6514745B1 (de)
EP (2) EP0728143B1 (de)
JP (3) JP2925740B2 (de)
AT (1) ATE233785T1 (de)
AU (2) AU700137B2 (de)
CA (2) CA2167302A1 (de)
DE (1) DE69432223T2 (de)
DK (1) DK0728143T3 (de)
ES (1) ES2191032T3 (de)
PT (1) PT728143E (de)
WO (2) WO1995003323A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US6001584A (en) 1993-07-19 1999-12-14 The Regents Of The University Of California Oncoprotein protein kinase
US6846644B2 (en) 1993-07-19 2005-01-25 The Regents Of The University Of California Oncoprotein protein kinase
US5925557A (en) * 1994-09-29 1999-07-20 The Regents Of The University Of California DNA encoding mitogen activated protein kinase, FRK
US6132978A (en) * 1995-12-19 2000-10-17 National Jewish Medical And Research Center Method to regulate CD40 signaling
EP0918851B1 (de) * 1996-08-16 2004-10-13 Genencor International, Inc. Expressionssystem abgeleitet von der lipase-regulationskaskade von pseudonomas alcaligenes
US5989885A (en) * 1997-01-10 1999-11-23 Myriad Genetics, Inc. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
EP0972019A1 (de) 1997-03-28 2000-01-19 The Research Foundation Of State University Of New York Antisense oligonukleotide für mitogen-antivierten protein-kinasen zur brustkrebs therapie
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6943000B2 (en) * 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use
EP1820854B1 (de) * 1997-10-03 2010-07-28 University of Massachusetts JNK3-Modulatoren und Verwendungsverfahren dafür
ATE344322T1 (de) * 1998-02-13 2006-11-15 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US6897019B1 (en) 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
EP0984070A1 (de) * 1998-08-31 2000-03-08 Boehringer Ingelheim International GmbH Verfahren zur Auffindung von Verbindungen für die Behandlung von Krankheiten die assoziert sind mit C-Jun vermittelte Apoptosis
AU2725000A (en) * 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
FR2788531B1 (fr) * 1999-01-20 2003-01-31 Aventis Pharma Sa Nouveaux polypeptides derives de la proteine jnk3 humaine, leurs variants, les sequences nucleotidiques correspondantes, et leurs utilisations
IL143950A0 (en) 1999-01-20 2002-04-21 Aventis Pharma Sa Polypeptides derived from jnk3
EP1196449B1 (de) 1999-06-28 2008-02-06 Inter-K Pty Limited Verfahren zur modulierung von integrin-vermittelter zellaktivitaet und hierfuer geeignete reagenzien
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7232897B2 (en) * 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
US7018999B2 (en) * 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
MXPA03010706A (es) * 2001-05-24 2004-05-27 Cephalon Inc Nuevo polipeptido de quinasa (7) (mlk7) de linaje mezclado polinucleotidos que codifican al mismo y metodos para su uso.
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics
WO2004026407A1 (en) * 2002-09-06 2004-04-01 Institut Curie Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP2007511203A (ja) * 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
US20050020391A1 (en) * 2003-07-17 2005-01-27 Pinnacle Sports Equipment Co., Inc. Bamboo bat and method of manufacture
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
WO2005037308A1 (en) 2003-10-17 2005-04-28 Inter-K Pty Limited Methods and agents for the treatment of cancer
KR20060134198A (ko) * 2004-04-08 2006-12-27 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｊｎｋ 저해제 및 시클로스포린을 포함하는 조성물
WO2009003211A1 (en) * 2007-06-29 2009-01-08 Newsouth Innovations Pty Limited Treatment of rheumatoid arthritis
AU2009217237A1 (en) * 2008-02-22 2009-08-27 Inter-K Pty Limited Therapeutic peptides
EP4000596A1 (de) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptid und zusammensetzungen mit tetrapeptiden

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599077A3 (de) * 1992-10-29 1994-11-23 Yeda Res & Dev Anti-metastatischer Impfstoff.

Also Published As

Publication number Publication date
EP0728143A4 (de) 1999-04-21
ES2191032T3 (es) 2003-09-01
US5994513A (en) 1999-11-30
US5804399A (en) 1998-09-08
CA2167302A1 (en) 1995-02-02
EP0726908A1 (de) 1996-08-21
WO1995003323A1 (en) 1995-02-02
US5605808A (en) 1997-02-25
JPH09500535A (ja) 1997-01-21
EP0728143A1 (de) 1996-08-28
AU7338094A (en) 1995-02-20
US6193965B1 (en) 2001-02-27
WO1995003324A1 (en) 1995-02-02
DK0728143T3 (da) 2003-07-07
PT728143E (pt) 2003-06-30
US6514745B1 (en) 2003-02-04
JP3745558B2 (ja) 2006-02-15
US5593884A (en) 1997-01-14
JP2986548B2 (ja) 1999-12-06
ATE233785T1 (de) 2003-03-15
EP0726908A4 (de) 1999-04-07
AU685484B2 (en) 1998-01-22
JPH09507384A (ja) 1997-07-29
AU700137B2 (en) 1998-12-24
AU7366894A (en) 1995-02-20
JP2925740B2 (ja) 1999-07-28
CA2166981C (en) 2000-11-07
JP2000023681A (ja) 2000-01-25
US5837244A (en) 1998-11-17
EP0728143B1 (de) 2003-03-05
DE69432223T2 (de) 2003-08-21

Similar Documents

Publication Publication Date Title
ATE233785T1 (de) Onkoprotein protein kinase
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
HUT77431A (hu) Fonálféregből kivont szerinproteáz-inhibitorok és véralvadásgátló proteinek
ATE490311T1 (de) Mutanten der alpha-amylase
DE60141546D1 (de) Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
ATE273718T1 (de) Methoxyethoxy-oligonukleotide zur regulierung der proteinkinase c expression
MXPA99001870A (es) Antagonistas del receptor de taquicinina,no peptidicos.
DE69825066D1 (de) Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
FI960089A (fi) Proteiinikinaasi C:n oligonukleotidimodulaatio
FR2819517B1 (fr) Composition comprenant un nitroxyde, un promoteur et eventuellement un initiateur de radicaux libres
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
EP1368467A4 (de) Putrescin-n-methyltransferasepromotor
DE59006687D1 (de) Dispersionen von Perfluoralkylgruppen enthaltenden Copolymerisaten.
DE69014046D1 (de) Verzweigungsenzym und dessen Verwendung.
ATE314477T1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
DE69432120D1 (de) Mit chemotherapeutische zusammensetzungenassoziierten genetischen suppressor-elementen
ATE310082T1 (de) Pflanzenpromoter und dessen verwendung zur genexpression
DK0506923T3 (da) Et collagenbindende protein samt fremstilling deraf
DE69838810D1 (de) Gen von alteromonas
DE59008462D1 (de) Stabilisatordispersionen.
FR2704749B1 (fr) Canule de pose d'une sonde ophtalmologique.
ATE356212T1 (de) O-fukosyltransferase
DE60025380D1 (de) Ein-schritttest zum nachweis von antimikrobiellen rückständen in eiern
ATE498014T1 (de) Identifizierung und funktionelle charakterisierung einer ribosomalen s6 proteinkinase

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation